Yale dermatologists identify six specific ethical tension points — nonmaleficence, scope of practice, prescribing cascades, patient autonomy, justice, and resource stewardship — when GLP-1 receptor agonists like semaglutide and tirzepatide are prescribed by dermatologists for elective aesthetic optimization rather than approved metabolic indications. The authors also flag dermatology-specific downstream harms including facial volume loss and telogen effluvium (diffuse hair shedding), conditions dermatologists may be managing without recognizing the GLP-1 RA as the precipitating cause.
This commentary arrives at a critical inflection point. GLP-1 receptor agonists have moved from diabetes management into mainstream weight-loss culture at extraordinary speed, and specialty creep — non-prescribing specialists beginning to prescribe powerful systemic agents — is a genuine patient safety concern. The facial fat atrophy problem, colloquially called 'Ozempic face,' is already generating a secondary aesthetic medicine market, creating a troubling iatrogenic loop where one cosmetic prescription generates demand for additional cosmetic procedures. The hair loss angle is particularly underappreciated clinically; telogen effluvium from rapid weight loss can persist six to nine months and is psychologically distressing. As an opinion-based ethical analysis rather than original clinical data, this paper carries no epidemiological weight but performs a valuable gatekeeping function. Its practical guardrails framework will matter most if adopted into dermatology training and board certification discourse. Incremental but timely.
